HOME - AnGes,Inc.

2019.02.12	AnGes and Kamada entered into agreement for the commercialization of HGF gene therapy product in Israel

2018.04.12	AnGes Announces First Patient Treated with DNA Vaccine for Hypertension in Phase I / II Clinical Study in Australia

2018.02.27	AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain

2018.01.22	AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

2017.04.25	AnGes Announces FDA Clearance of Investigational New Drug (IND) Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain

2017.03.24	Investigational New Drug (IND) Application Submitted to the FDA Initiating a clinical trial with NF-kappaB decoy for the treatment of discogenic lower back pain

2017.02.20	Announcement Regarding Decrease in the Amount of Stated Capital and Capital Reserve and Appropriation of Surplus

2018.02.23	Notice of Convocation Annual General Meeting 2018

2018.02.02	Consolidated Financial Report for 2017

2017.03.02	Notice of Convocation Annual General Meeting 2017

2017.02.03	Consolidated Financial Report for 2016

2015.06.05	AnGes will attend the 2015 BIO International Convention on June 15th-18th in Philadelphia, PA